Inclusion Criteria:  Pathologically confirmed invasive breast cancer, clinically stage I-II. Clinically lymph node negative Eligible for anti-endocrine treatment (per medical oncologist) Postmenopausal women Ability to understand and the willingness to sign a written informed consent document  Exclusion Criteria:  Progesterone receptor negativity High grade tumor Synchronous non-breast malignancy Receiving any other investigational agents that could impact the efficacy of this trial regimen History of allergic reactions attributed to compounds of similar chemical or biologic composition to Anastrozole, Letrozole, Exemestane, Tamoxifen or other agents used in study Uncontrolled intercurrent illness Medical, psychiatric or other condition and/or social situations that would limit compliance with study requirements